Publications by authors named "Cynthia Robinson"

Claim this Profile
S
Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancy.
Gloria Aguilar, Gabriela Tapia-Calle, Cynthia Robinson, Benoit Baron, David Lowson

Hum Vaccin Immunother· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterologous two-dose Ebola vaccine regimen in pregnant women in Rwanda: a randomized controlled phase 3 trial.
Julien Nyombayire, Rosine Ingabire, Amelia Mazzei, Tyronza Sharkey, Claudine Umuhoza, Cynthia Robinson

Nat Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Facebook as a Strategy To Deliver a Peer Navigation Intervention for Recently Incarcerated Women with Opioid Use Disorder: A Mixed Methods Descriptive Profile.
Martha Tillson, Jaxin Annett, Marguerite A Webster, Amanda Fallin-Bennett, Mandi Webster, Cynthia Robinson

Community Ment Health J· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filoviruses.
Thembi Mdluli, Suzanne Wollen-Roberts, Mélanie Merbah, Bradley Beckman, Yifan Li, Cynthia Robinson

Sci Transl Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial.
Christine Lacabaratz, Mélany Durand, Aurélie Wiedemann, Emile Foucat, Mathieu Surénaud, Cynthia Robinson

J Infect Dis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial.
Neil Goldstein, Chelsea McLean, Auguste Gaddah, Joachim Doua, Babajide Keshinro, Cynthia Robinson

Hum Vaccin Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of Accelerated Heterologous 2-Dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa.
Betty Mwesigwa, Fredrick Sawe, Janet Oyieko, Joel Mwakisisile, Edna Viegas, Cynthia Robinson

Clin Infect Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial.
Ynke Larivière, Trésor Zola Matuvanga, Bernard Isekah Osang'ir, Solange Milolo, Rachel Meta, Cynthia Robinson

Lancet Infect Dis· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delivery and Safety of a Two-Dose Preventive Ebola Virus Disease Vaccine in Pregnant and Non-Pregnant Participants during an Outbreak in the Democratic Republic of the Congo.
Hugo Kavunga-Membo, Deborah Watson-Jones, Kambale Kasonia, Tansy Edwards, Anton Camacho, Cynthia Robinson

Vaccines (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo.
Edward Man-Lik Choi, Kambale Kasonia, Hugo Kavunga-Membo, Daniel Mukadi-Bamuleka, Aboubacar Soumah, Cynthia Robinson

Vaccines (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial.
Julie A Ake, Kristopher Paolino, Jack N Hutter, Susan Biggs Cicatelli, Leigh Anne Eller, Cynthia Robinson

Vaccines (Basel)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo.
Ynke Larivière, Irene Garcia-Fogeda, Trésor Zola Matuvanga, Bernard Isekah Osang'ir, Solange Milolo, Cynthia Robinson

J Infect Dis· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen.
Houreratou Barry, Edouard Lhomme, Mathieu Surénaud, Moumini Nouctara, Cynthia Robinson

PLoS Negl Trop Dis· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study.
Adeep Puri, Andrew J Pollard, Catherine Schmidt-Mutter, Fabrice Lainé, George PrayGod, Cynthia Robinson

Vaccines (Basel)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda.
Edward Man-Lik Choi, Ggayi Abu-Baker Mustapher, Gloria Omosa-Manyonyi, Julie Foster, Zacchaeus Anywaine, Cynthia Robinson

Vaccine· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone.
Edward Man-Lik Choi, Boris Lacarra, Muhammed O Afolabi, Boni Maxime Ale, Frank Baiden, Cynthia Robinson

Lancet Glob Health· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans.
Chelsea McLean, Karin Dijkman, Auguste Gaddah, Babajide Keshinro, Michael Katwere, Cynthia Robinson

Front Immunol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen.
Daniela Manno, Catriona Patterson, Abdoulie Drammeh, Kevin Tetteh, Mattu Tehtor Kroma, Cynthia Robinson

Vaccines (Basel)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory.
Chelsea McLean, Houreratou Barry, Mark Kieh, Zacchaeus Anywaine, Baimba Tapima Rogers, Cynthia Robinson

EBioMedicine· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial.
Daniela Manno, Agnes Bangura, Frank Baiden, Abu Bakarr Kamara, Philip Ayieko, Cynthia Robinson

Lancet Infect Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.
Julien Nyombayire, Rosine Ingabire, Ben Magod, Amelia Mazzei, Jean-Baptiste Mazarati, Cynthia Robinson

J Infect Dis· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.
Viki Bockstal, Maarten Leyssen, Dirk Heerwegh, Bart Spiessens, Cynthia Robinson

NPJ Vaccines· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
Viki Bockstal, Georgi Shukarev, Chelsea McLean, Neil Goldstein, Stephan Bart, Cynthia Robinson

PLoS One· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial.
Etienne Karita, Julien Nyombayire, Rosine Ingabire, Amelia Mazzei, Tyronza Sharkey, Cynthia Robinson

Trials· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone.
Daniela Manno, Philip Ayieko, David Ishola, Muhammed O Afolabi, Baimba Rogers, Cynthia Robinson

Emerg Infect Dis· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis